<p>Inotiv Inc., a leading contract research organization specializing in drug discovery and development services, has announced a strategic partnership with VUGENE, a multi-omics data analysis company. Through this collaboration, Inotiv will integrate VUGENE’s cloud-based bioinformatics and computational platform into its Discovery &amp; Translational Sciences Division. The partnership aims to enhance Inotiv’s capabilities in analyzing complex biological data, including epigenomic and proteomic datasets, and to accelerate AI-assisted drug discovery. Both companies expect the alliance to improve the prediction of drug efficacy and safety in early-stage research and to help clients make faster, more informed decisions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inotiv Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600741) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

NOTV

<p>Inotiv Inc. partners with VUGENE to integrate cloud-based bioinformatics into its Discovery & Translational Sciences Division, aiming to boost AI-driven drug discovery. The collaboration will enhance analysis of complex biological data and improve prediction of drug efficacy and safety, aiding faster decision-making in early-stage research.</p>

Inotiv Partners with VUGENE to Boost AI-Driven Drug Discovery